Vaxcyte

Vaxcyte’s Powering Beyond Awards program recognizes team members who have gone above and beyond in modeling our core values: Rethink Convention, Aim High, Lead with Heart and Model Excellence. Our second annual award recipients were celebrated by our CEO and Co-Founder, Grant Pickering, and the entire Company, recognizing the contributions of this impressive group. Congratulations to Charlotte Tsang, David Burk, Lue Tao, Rebecca McGahey, PMP and Peter Davey. Your dedication and hard work have made a significant impact in advancing our mission to protect humankind.

We are excited to share that Vaxcyte has been recertified as a Great Place to Work for 2025 with 95% of our employees sharing that Vaxcyte is a great place to work! We’re proud of the incredible company and culture we have built together at Vaxcyte—one that fosters an environment where people feel valued, supported and empowered to do their best work. Learn more about our company and additional survey insights on our Great Place to Work Certification page: https://lnkd.in/gxPHBaSb

Today, we shared our Q4/FY 2024 financial results and business update, which reflect a transformative year for Vaxcyte. We continue to make meaningful progress across our adult and infant pneumococcal conjugate vaccine (PCV) programs, comprising VAX-31 and VAX-24, reinforcing the potential of our carrier-sparing platform to set a new standard in protection against invasive pneumococcal disease. We are also advancing our early-stage pipeline, including candidates targeting Group A Strep and Shigella, which, along with Streptococcus pneumoniae, are among the top antibiotic-resistant pathogens requiring urgent solutions.   At Vaxcyte, our mission remains clear: to deliver broad-spectrum vaccines that address significant unmet needs. We are optimistic about the strength of our science and the broad understanding of the critical role vaccines play in protecting global health.   Read more here: https://lnkd.in/gMVWQA9D   #biotechnology #vaccines #publichealth

We’re pleased to share our third quarter 2024 financial results and business update as we continue to build momentum across our broad-spectrum pneumococcal conjugate vaccine (PCV) franchise, VAX-31 and VAX-24. We believe the recent topline results for VAX-31 in adults demonstrate its potential as a best-in-class PCV to provide protection against both currently circulating and historically prevalent strains while setting a new standard for immunogenicity.   We are well-positioned to maintain continued positive momentum across our PCVs, including the advancement of multiple adult and infant clinical studies and key steps to ensure global manufacturing readiness for the large, well-established pediatric population and the expanding adult market. https://lnkd.in/g2_eKHna #Vaxcyte #PCV #Vaccines #PublicHealth

Vaxcyte's Halloween 2024 Celebration was a treat! Our colleagues outdid themselves once again with this year’s costumes, serving up some seriously creative looks. Check out members of our Protein group below! #TeamCulture #Halloween

We're thrilled to share that Vaxcyte has been recognized by Great Place to Work in five categories, honoring our vibrant and values-driven culture: • #𝟰 Best National Workplaces in BioPharma • #𝟭𝟭 Best Small & Medium Workplaces in the Bay Area • #𝟮𝟵 Best National Small & Medium Workplaces for Women • #𝟱𝟬 Best National Medium Workplaces • #𝟳𝟱 Best National Workplaces for Millennials The passion, dedication and collaboration of our Vaxcyte colleagues made this possible, and we thank you all for your many contributions that propel us to deliver on our mission to protect humankind. Check out our Great Place to Work page here: https://lnkd.in/gxPHBaSb. Join us on our mission - explore our career opportunities: https://lnkd.in/g54g7pNx #GreatPlacetoWork #culture #biotech

We're thrilled to announce that our President and CFO, Andrew Guggenhime, has been named a Bay Area CFO of the Year! Andrew's exceptional leadership and financial expertise have been crucial in advancing our mission to protect humankind from the consequences of bacterial infections, and this well-deserved honor recognizes his significant contributions to both Vaxcyte and the broader biotech industry. Congratulations, Andrew! Your dedication to our Company and our mission is truly inspiring. Read more about Andrew here: https://lnkd.in/dJ_Hfmu2 #BayAreaCFOOfTheYearAwards #CFOVisionaries2024 #SupportLarkinStreet

Behind our innovative technology is a team of passionate individuals collaborating to re-engineer high-fidelity vaccines at scale. All of our employees play a part in realizing our goal of developing vaccines that prevent or treat some of the most invasive bacterial diseases in circulation today. Hear more from Vaxcyte’s leaders about how our team is going beyond to protect humankind. #vaccineinnovation #biotech #culture

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV

Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs.   We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team.   For more, read the full press release here: https://lnkd.in/g72D5AUd  #Vaccines #Biotechnology #ProtectHumankind #PCV